<i>Mycobacterium tuberculosis</i> Rv2005c Induces Dendritic Cell Maturation and Th1 Responses and Exhibits Immunotherapeutic Activity by Fusion with the Rv2882c Protein

• Main Authors: Yong Woo Back, Ki Won Shin, Seunga Choi, Hye-Soo Park, Kang-In Lee, Han-Gyu Choi, Hwa-Jung Kim
• Format: Article
• Language: English
• Published: MDPI AG 2020-07-01
• Series: Vaccines
• Subjects: <i>Mycobacterium tuberculosis</i>; hypoxia; DosR; chemo-immunotherapy; multifunctional T cell
• Online Access: https://www.mdpi.com/2076-393X/8/3/370

Immunotherapy represents a promising approach for improving current antibiotic treatments through the engagement of the host’s immune system. Latency-associated antigens have been included as components of multistage subunit tuberculosis vaccines. We first identified Rv2005c, a DosR regulon-encoded protein, as a seroreactive protein. In this study, we found that Rv2005c induced dendritic cell (DC) maturation and Th1 responses, and its expression by <i>Mycobacterium tuberculosis</i> (Mtb) within macrophages was enhanced by treatment with CoCl₂, a hypoxia-mimetic agent. T cells activated by Rv2005c-matured DCs induced antimycobacterial activity in macrophages under hypoxic conditions but not under normoxic conditions. However, Rv2005c alone did not exhibit any significant vaccine efficacy in our mouse model. The fusion of Rv2005c to the macrophage-activating protein Rv2882c resulted in significant activation of DCs and antimycobacterial activity in macrophages, which were enhanced under hypoxic conditions. Furthermore, the Rv2882c-Rv2005c fusion protein showed significant adjunctive immunotherapeutic effects and led to the generation of long-lasting, antigen-specific, multifunctional CD4⁺ T cells that coproduced TNF-α, IFN-γ and IL-2 in the lungs of our established mouse model. Overall, these results provide a novel fusion protein with immunotherapeutic potential as adjunctive chemotherapy for tuberculosis.